BioCentury
ARTICLE | Company News

Peregrine, AstraZeneca deal

November 16, 2015 8:00 AM UTC

The companies expanded an August deal and will evaluate Peregrine’s bavituximab with AstraZeneca’s durvalumab in an international Phase II trial in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The original deal covered a Phase I/Ib trial to treat multiple solid tumors. Peregrine will conduct both trials, which are expected to start next year. ...